Valiant Laboratories Limited (NSE:VALIANTLAB)

Market Cap	5.20B +8.7%
Revenue (ttm)	3.06B +89.6%
Net Income	160.14M +12,314.1%
EPS	2.40 +7,963.7%
Shares Out	54.31M
PE Ratio	39.94
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	360,356
Open	93.90
Previous Close	91.66
Day's Range	90.94 - 96.24
52-Week Range	49.51 - 96.21
Beta	0.95
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Valiant Laboratories

Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1980
• Employees: 79
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: VALIANTLAB

Financial Performance

In fiscal year 2026, Valiant Laboratories's revenue was 2.37 billion, an increase of 78.04% compared to the previous year's 1.33 billion. Losses were -32.68 million, 48.5% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error